BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $40.23 Average PT from Analysts
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average […]
More Stories
Centaurus Financial Inc. Has $4.69 Million Stake in Costco Wholesale Co. (NASDAQ:COST)
Centaurus Financial Inc. boosted its holdings in Costco Wholesale Co. (NASDAQ:COST – Free Report) by 2.2% in the third quarter,...
Vertigo: Symptoms, Causes, Treatments, and Natural Approaches
By Mercura Wang Vertigo is a form of dizziness in which a person feels like they are moving even though...
The Goldman Sachs Group, Inc. (NYSE:GS) Stake Raised by SevenBridge Financial Group LLC
SevenBridge Financial Group LLC grew its holdings in The Goldman Sachs Group, Inc. (NYSE:GS – Free Report) by 6.7% during...
Hartford Funds Management Co LLC Increases Stock Holdings in Vanguard Value ETF (NYSEARCA:VTV)
Hartford Funds Management Co LLC increased its stake in Vanguard Value ETF (NYSEARCA:VTV – Free Report) by 50.1% in the...
Lane & Associates LLC Has $344,000 Stock Holdings in The Goldman Sachs Group, Inc. (NYSE:GS)
Lane & Associates LLC cut its holdings in The Goldman Sachs Group, Inc. (NYSE:GS – Free Report) by 9.7% in...
Daiwa Securities Group Inc. Raises Stake in Bank of America Co. (NYSE:BAC)
Daiwa Securities Group Inc. boosted its holdings in Bank of America Co. (NYSE:BAC) by 17.6% during the third quarter, according...